+ General Considerations

  • Histologic types: leiomyosarcoma, FSA, undifferentiated sarcoma, liposarcoma, OSA, CSA, myxosarcoma, rhabdomyosarcoma, and fibrous histiocytoma
  • Clinical signs: inappetence, abdominal distension, polydipsia, lethargy, vomiting, weight loss, and weakness
  • Abdominal mass frequently detected with abdominal palpation and survey abdominal radiographs
  • Treatment: splenectomy
  • Prognosis is guarded to poor with overall MST 10 weeks
  • MST 1 month for dogs with evidence of metastatic disease at surgery
  • MST 9 months for dogs with no evidence of metastatic disease at surgery

+ Splenic Nodular Hyperplasia

  • Splenic nodular hyperplasia can be classified according to type and proportion of cellular components:
  • Lymphoid
  • Hematopoietic
  • Plasmocytic
  • Fibrohistiocytic
  • Mixed

+ Nodular Fibrohistiocytic Hyperplasia

  • Nodular fibrohistiocytic hyperplasia may represent a transitional form between nodule and malignant neoplasia (i.e., malignant fibrous histiocytoma or generalized histiocytic sarcoma)
  • Nodular fibrohistiocytic proliferation in canine spleen characterized by a mixed population of spindle cells in varying proportions with hematopoietic elements, plasma cells, and lymphocytes
  • MST 5.0-5.5 months, with 12-month survival rate 48%
  • 44% of deaths directly attributable to splenic disease
  • Poor prognostic factors include low lymphoid-to-fibrohistiocytic ratio and high mitotic index

+ Survival

  • 0-9 cells per 10 high power fields
  • 12-month survival rate 40%
  • greater than 9 cells per 10 high power fields
  • MST 1 month